| Vincent Edouard Retardo Gullas, MD | |
|
500 J Clyde Morris Blvd, Newport News, VA 23601-1929 | |
| (757) 594-3580 | |
| Not Available |
| Full Name | Vincent Edouard Retardo Gullas |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 500 J Clyde Morris Blvd, Newport News, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578125381 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 0101274265 (Virginia) | Primary |
| 207R00000X | Internal Medicine | 125073772 (Illinois) | Secondary |
| Entity Name | Riverside Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194929026 PECOS PAC ID: 5092608448 Enrollment ID: O20040207000400 |
News Archive
The researchers, who encountered this genetic property while working on an unrelated project, believe that this discovery could lead to the use of genetically engineered phages to treat bacterial infections that have become resistant to antibiotics.
Texas Attorney General Greg Abbott has announced a settlement among Texas and other states with pharmaceutical giant Schering-Plough Inc. that will return more than $9 million to the Texas Medicaid program for the company's fraudulent reporting of prices for the antihistamine drug Claritin.
Working with mice, Johns Hopkins researchers report they have identified chemical signals that certain breast cancers use to recruit two types of normal cells needed for the cancers' spread.
Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.
Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company's revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vincent Edouard Retardo Gullas, MD 856 J Clyde Morris Blvd Ste A, Newport News, VA 23601-1318 Ph: (757) 316-5800 | Vincent Edouard Retardo Gullas, MD 500 J Clyde Morris Blvd, Newport News, VA 23601-1929 Ph: (757) 594-3580 |
News Archive
The researchers, who encountered this genetic property while working on an unrelated project, believe that this discovery could lead to the use of genetically engineered phages to treat bacterial infections that have become resistant to antibiotics.
Texas Attorney General Greg Abbott has announced a settlement among Texas and other states with pharmaceutical giant Schering-Plough Inc. that will return more than $9 million to the Texas Medicaid program for the company's fraudulent reporting of prices for the antihistamine drug Claritin.
Working with mice, Johns Hopkins researchers report they have identified chemical signals that certain breast cancers use to recruit two types of normal cells needed for the cancers' spread.
Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.
Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company's revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.
› Verified 4 days ago
Xia Li, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2 Bernardine Dr, Newport News, VA 23602 Phone: 757-886-6877 Fax: 757-947-3232 | |
Margaret Tajak, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-594-3580 Fax: 757-594-3653 | |
Rachel Amitta Paul-jeyadhas, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-594-3580 Fax: 757-594-3653 | |
Dr. David Stanton Deeley, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12655 Warwick Blvd, Suite A, Newport News, VA 23606 Phone: 757-595-9880 Fax: 757-595-0362 | |
Dana Davis Covington, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-594-3580 Fax: 757-594-3653 | |
Melissa Wilbur, DO Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-594-3580 | |
Dr. Mark Winston Hargrove, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-594-3580 |